Epirubicin
Adenocarcinoma of Lung
Tango Therapeutics, Inc.Phase 2Active
B
63/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 95/ 100
Competitive context
13 Active assets in the Adenocarcinoma of Lung cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Anusha Kalbasi | Phase 2 | BBB |
Osimertinib Shanghai Chest Hospital | Phase 2 | BB |
Ct-P16 Celltrion | Phase 3 | BB |
Durvalumab University of British Columbia | Phase 2 | B |
Fludarabine Anusha Kalbasi | Phase 1/2 | B |
View all 22 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →